Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NeoVista's wet age-related macular degeneration device:

This article was originally published in Clinica

Executive Summary

Fremont, California-based NeoVista has CE marked its focal epiretinal brachytherapy device for sale in Europe. The wet age-related macular degeneration (AMD) therapy delivers focused beta radiation - using strontium 90 - to the leaking blood vessels that affect central vision, without causing damage to the surrounding tissues. The company says that preliminary data show it to be safe for both the patient and the physician and may be able to reverse vision loss. NeoVista is currently conducting the final US phase III clinical trial required to gain US approval for the technology.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046621

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel